Literature DB >> 10683861

Serotonin transporter gene polymorphism and antidepressant response.

D K Kim1, S W Lim, S Lee, S E Sohn, S Kim, C G Hahn, B J Carroll.   

Abstract

We examined allelic polymorphisms of the serotonin transporter (5-HTT) gene and antidepressant response to 6 weeks' treatment with the selective serotonin reuptake inhibitor (SSRI) drugs fluoxetine or paroxetine. We genotyped 120 patients and 252 normal controls, using polymerase chain reaction of genomic DNA with primers flanking the second intron and promoter regions of the 5-HTT gene. Diagnosis of depression was not associated with 5-HTT polymorphisms. Patients homozygous l/l in intron 2 or homozygous s/s in the promoter region showed better responses than all others (p < 0.0001, p = 0.0074, respectively). Lack of the l/l allele form in intron 2 most powerfully predicted non-response (83.3%). Response to SSRI drugs is related to allelic variation in the 5-HTT gene in depressed Korean patients.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10683861     DOI: 10.1097/00001756-200001170-00042

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  73 in total

Review 1.  Role of pharmacogenomics in individualising treatment with SSRIs.

Authors:  Dalu Mancama; Robert W Kerwin
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

2.  Pharmacogenetics in mood disorder.

Authors:  Charles U Nnadi; Joseph F Goldberg; Anil K Malhotra
Journal:  Curr Opin Psychiatry       Date:  2005-01       Impact factor: 4.741

3.  Simulation for population pharmacodynamic analysis of dose-ranging trials: usefulness of the mixture model analysis for detecting nonresponders.

Authors:  Takeshi Shiiki; Yukiya Hashimoto; Ken-ichi Inui
Journal:  Pharm Res       Date:  2002-06       Impact factor: 4.200

4.  The serotonin transporter polymorphism, 5HTTLPR, is associated with a faster response time to sertraline in an elderly population with major depressive disorder.

Authors:  L Kathryn Durham; Suzin M Webb; Patrice M Milos; Cathryn M Clary; Albert B Seymour
Journal:  Psychopharmacology (Berl)       Date:  2003-09-04       Impact factor: 4.530

Review 5.  Pharmacogenetics and psychiatry.

Authors:  Amlan Basu; Eva Tsapakis; Kathy Aitchison
Journal:  Curr Psychiatry Rep       Date:  2004-04       Impact factor: 5.285

Review 6.  Vesicular and plasma membrane transporters for neurotransmitters.

Authors:  Randy D Blakely; Robert H Edwards
Journal:  Cold Spring Harb Perspect Biol       Date:  2012-02-01       Impact factor: 10.005

Review 7.  Pharmacogenetics of antidepressant response.

Authors:  Stefano Porcelli; Antonio Drago; Chiara Fabbri; Sara Gibiino; Raffaella Calati; Alessandro Serretti
Journal:  J Psychiatry Neurosci       Date:  2011-03       Impact factor: 6.186

8.  Is 5-HTTLPR linked to the response of selective serotonin reuptake inhibitors in MDD?

Authors:  Ari Illi; Outi Poutanen; Eija Setälä-Soikkeli; Olli Kampman; Merja Viikki; Heini Huhtala; Nina Mononen; Susann Haraldsson; Pasi A Koivisto; Esa Leinonen; Terho Lehtimäki
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2010-07-17       Impact factor: 5.270

9.  Serotonin transporter gene (SLC6A4) polymorphisms are associated with response to fluoxetine in south Indian major depressive disorder patients.

Authors:  Aarthi Manoharan; Deepak Gopal Shewade; Ravi Philip Rajkumar; Surendiran Adithan
Journal:  Eur J Clin Pharmacol       Date:  2016-07-20       Impact factor: 2.953

10.  Clinical efficacy of fluvoxamine and functional polymorphism in a serotonin transporter gene on childhood autism.

Authors:  Yoko Sugie; Hideo Sugie; Tokiko Fukuda; Masataka Ito; Yumiko Sasada; Mutsumi Nakabayashi; Kazunobu Fukashiro; Takehiko Ohzeki
Journal:  J Autism Dev Disord       Date:  2005-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.